Evidence map›Paper›PMID 41101975›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.

Sean R Miller, Dana H Chung, Rachel T Gonzalez, William C Jackson, Megan E V Caram, Phoebe A Tsao, Kristian Stensland, Roman Gulati, Yashesh Shah, Daniel Wale and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sean R MillerDepartment of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Dana H ChungUniversity of Michigan School of Medicine, Ann Arbor, Michigan.
Rachel T GonzalezDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
William C JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Megan E V CaramDivision of Medical Oncology, Department of Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Phoebe A TsaoDivision of Medical Oncology, Department of Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Kristian StenslandVeterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
Roman GulatiDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
Yashesh ShahDivision of Nuclear Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan; and.
Daniel WaleDivision of Nuclear Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan; and.
David ElliottDepartment of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Tanner CaverlyVeterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
Timothy P HoferVeterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
Sameer SainiVeterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
Michael D GreenDepartment of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Matthew SchipperDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Robert T DessDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Alex K BryantDepartment of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan; bralex@med.umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) PET/CT has become a common staging modality for newly diagnosed high-risk and unfavorable intermediate-risk prostate cancer after showing improved sensitivity and specificity compared with conventional imaging in clinical trials. We aimed to assess the causal impact of PSMA PET staging on initial treatment selection in real-world practice.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm StagingAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIemulated trialPET/CTprostate cancerPSMAstaging

Identifiers

PMID41101975
PMCPMC12676669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.